Pulmatrix Inc (PULM) - Total Liabilities
Based on the latest financial reports, Pulmatrix Inc (PULM) has total liabilities worth $905.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pulmatrix Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Pulmatrix Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Pulmatrix Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Pulmatrix Inc's balance sheet.
Pulmatrix Inc Competitors by Total Liabilities
The table below lists competitors of Pulmatrix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nichols
LSE:NICL
|
UK | GBX39.26 Million |
|
Erika Carmel-Tech Ltd
TA:ERKA
|
Israel | ILA21.86 Million |
|
Impex Ferro Tech Limited
NSE:IMPEXFERRO
|
India | Rs4.81 Billion |
|
Adneo Ltd
AU:AD1
|
Australia | AU$16.62 Million |
|
Ahlada Engineers Limited
NSE:AHLADA
|
India | Rs892.11 Million |
|
Elecster Oyj A
HE:ELEAV
|
Finland | €17.36 Million |
|
Ranplan Group
ST:RPLAN
|
Sweden | Skr14.91 Million |
|
GEOTRANS S.A. ZY -10
F:5Z4
|
Germany | €5.76 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Pulmatrix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Pulmatrix Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulmatrix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulmatrix Inc (2012–2025)
The table below shows the annual total liabilities of Pulmatrix Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $329.00K | -66.97% |
| 2024-12-31 | $996.00K | -93.76% |
| 2023-12-31 | $15.96 Million | +62.16% |
| 2022-12-31 | $9.84 Million | -13.41% |
| 2021-12-31 | $11.37 Million | -24.36% |
| 2020-12-31 | $15.03 Million | -40.07% |
| 2019-12-31 | $25.08 Million | +771.10% |
| 2018-12-31 | $2.88 Million | -50.71% |
| 2017-12-31 | $5.84 Million | -26.08% |
| 2016-12-31 | $7.90 Million | -35.58% |
| 2015-12-31 | $12.27 Million | +1195.35% |
| 2014-12-31 | $947.00K | 0.00% |
| 2013-12-31 | $947.00K | +837.62% |
| 2012-12-31 | $101.00K | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more